Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia

International Journal of Breast Cancer
Nadia HussainZainab Khan

Abstract

To evaluate the safety issues and adverse effects of using TCHP regimen (docetaxel, carboplatin, trastuzumab, and pertuzumab) versus TCP regimen (docetaxel, carboplatin, and trastuzumab) in older postmenopausal women with nonmetastatic HER2-positive breast cancer. HER2 overexpressed in 20-25% of breast cancer signals an aggressive form of breast cancer and is treated with trastuzumab and pertuzumab. The patient record database was accessed to identify all postmenopausal women in the Punjab Care hospital who were above 65 years old, with stages 1-3 HER2-positive breast cancer and treated with neoadjuvant TCHP and neoadjuvant TCP from 2013 till 2016. In TCH-P group and TCH group, mild fatigue (34% versus 36%) and diarrhea (48% versus 49%) were most common toxicities. Fever in TCH-P group and TCH group (12% versus 13%) was common. Anorexia affected 21% and 16% of patients receiving TCH and TCHP regimen, respectively. Febrile neutropenia was higher in TCH-P group 13% (3/23) versus 4.5% (1/22) in TCH group. Also 27.2% (6/22) of TCH-P group was hospitalized for treatment related toxicities versus 21.7% (5/23) of TCH group. Comparing neoadjuvant TCP and neoadjuvant TCH-P showed TCH-P regimen had an acceptable toxicity profile. Severe ...Continue Reading

References

Apr 20, 2004·Cancer Cell·Matthew C FranklinMark X Sliwkowski
May 4, 2004·Nature Reviews. Cancer·Andreas GschwindAxel Ullrich
Sep 28, 2006·Breast Cancer Research and Treatment·Cynthia OwusuRebecca A Silliman
May 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hyman B MussMatti Aapro
Mar 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonino MusolinoAndrea Ardizzoni
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neil L Spector, Kimberly L Blackwell
Oct 14, 2011·The New England Journal of Medicine·Dennis SlamonUNKNOWN Breast Cancer International Research Group
Nov 10, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Benjamin D SmithThomas A Buchholz
Nov 30, 2012·The New England Journal of Medicine·Gregory M CoteBruce A Chabner
Jul 23, 2013·Lancet·Aron GoldhirschUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Aug 7, 2013·Hematology/oncology Clinics of North America·Grant R WilliamsHyman B Muss
Mar 17, 2016·Expert Opinion on Drug Safety·Jennifer Gao, Sandra M Swain
Aug 9, 2016·The Breast : Official Journal of the European Society of Mastology·Mette S van RamshorstUNKNOWN Dutch Breast Cancer Research Group (BOOG)
Jun 6, 2017·The New England Journal of Medicine·Gunter von MinckwitzUNKNOWN APHINITY Steering Committee and Investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Related Papers

Nan fang yi ke da xue xue bao = Journal of Southern Medical University
Ning LiaoKun Wang
Annals of Oncology : Official Journal of the European Society for Medical Oncology
Sandra M SwainJosé Baselga
Clinical Advances in Hematology & Oncology : H&O
Mikkael A Sekeres
© 2022 Meta ULC. All rights reserved